Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Research
  • Published:

Preclinical safety profile of sildenafil

Abstract

Sildenafil citrate, marketed as Viagra®, for the treatment of erectile dysfunction, has a proven record of safety in humans as predicted by the results of extensive pharmacological and toxicological testing in animals and in vitro, and confirmed by pharmacokinetic exposure data. The aim of this paper is to review succinctly the main findings resulting from these experiments. Daily doses of sildenafil, within and far beyond the human therapeutic range, were given to dogs and rodents for up to 1 and 2 y, respectively. Plasma analyses were conducted to determine the exposure to sildenafil. We found species-specific effects in dogs (Beagle pain syndrome), mice (marked intestinal dilatation) and rats (adaptive reversible hepatocellular hypertrophy associated with secondary thyroid hypertrophy). All these effects in rodents and dogs have no relevance to humans. Morphometric thickness measurements of the retinal layers carried out in response to clinical observations of visual disturbances in humans indicated no difference between treated and control rats and dogs after up to 24 months of treatment. There was no evidence of histopathologic damage to any structures of the visual pathway. Sildenafil had no effects on fertility, no teratogenic potential, was not genotoxic and has no carcinogenic potential. In rats and dogs, safety ratios were 40:1 and 28:1, respectively, in terms of exposure over 24 h (AUC24 h) and 19:1 and 8:1, respectively, in terms of peak plasma concentration (Cmax). These safety ratios illustrate the separation between exposure to sildenafil of animals at large nontoxic doses and the much smaller human therapeutic exposure. This profile highlights the very low risk of human toxicity for sildenafil. The favourable results of the nonclinical safety evaluation of sildenafil in established animal models have been confirmed by many years of clinical experience during the development and marketing of sildenafil.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. USFDA. Center for Drug Evaluation and Research Application Number NDA 20-895 Pharmacology Reviews.

  2. CPMP/1136/98 rev 2 Scientific Discussion ©EMEA. 2000.

  3. ICH: Guidance on Non-Clinical Safety Evaluation.

  4. Nicholson CD, Challiss RAJ, Shahid M . Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TiPS 1991; 12: 19–27.

    CAS  PubMed  Google Scholar 

  5. Geelen P et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 2000; 102: 275–277.

    Article  CAS  Google Scholar 

  6. Zusman RM, Morales A, Glasser DB, Osterloh IH . Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83: 35C–44C.

    Article  CAS  Google Scholar 

  7. Comer CP, Chengelis CP, Levin S, Kotsoris FN . Changes in thyroidal function and liver UDP glucurosyl transferase activity in rats following administration of a novel imidazole (SC-37211). Toxicol Appl Pharmacol 1985; 80: 427–436.

    Article  CAS  Google Scholar 

  8. Lumb GD, Rust JH . The pathologic response of the liver and thyroid of the rat to potassium prorenoate (SC-23992). Toxicol Pathol 1985; 13: 315–324.

    Article  CAS  Google Scholar 

  9. Hill RN et al. Thyroid follicular cell carcinogenesis. Fundam Appl Toxicol 1989; 12: 629–697.

    Article  CAS  Google Scholar 

  10. McClain RM, Posch RC, Bosakowski T, Armstrong JM . Studies on the mode of action for thyroid gland tumour promotion in rats by phenobarbital. Toxicol Appl Pharmacol 1988; 94: 254–265.

    Article  CAS  Google Scholar 

  11. McClain RM . The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: implications for thyroid gland neoplasia. Toxicol Pathol 1989; 17: 294–306.

    Article  CAS  Google Scholar 

  12. Johnson S, McKillop D, Miller J, Smith IK . The effects on rat thyroid function of a hepatic microsomal enzyme inducer. Hum Exp Toxicol 1993; 12: 153–158.

    Article  CAS  Google Scholar 

  13. Davies DT . Assessment of rodent thyroid endocrinology: advantages and pit-falls. Comp Haematol Int 1993; 3: 142–152.

    Article  CAS  Google Scholar 

  14. Hayes TJ, Roberts GKS, Halliwell WH . An idiopathic febrile necrotizing arteritis syndrome in the dog: beagle pain syndrome. Toxicol Pathol 1989; 17: 129–137.

    Article  CAS  Google Scholar 

  15. Snyder PW et al. Pathologic features of naturally occurring juvenile polyarteritis in Beagle dogs. Vet Pathol 1995; 32: 337–345.

    Article  CAS  Google Scholar 

  16. Stejskal V, Havu N, Malmfors T . Necrotizing vasculitis as an immunological complication in toxicity study. New Toxicology for Old. Arch Toxicol 1982; (Suppl 5): 283–286.

  17. Ruben Z et al. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: a possible genetic predilection. Toxicol Pathol 1989; 17: 145–152.

    Article  CAS  Google Scholar 

  18. Schlaeppi B, Roncari G, Zahm P . Vascular toxicity in dogs associated with overdoses of a novel benzodiazepine receptor partial agonist. Arch Toxicol 1991; 65: 73–80.

    Article  CAS  Google Scholar 

  19. Detweiler DK . Spontaneous and induced arterial disease in the dog: pathology and pathogenesis. Toxicol Pathol 1989; 17: 94–108.

    Article  CAS  Google Scholar 

  20. Kerns WD, Roth L, Hosokawa S . Idiopathic canine polyarteritis. In: Mohr U, Carlton WW, Dungworth DL, Benjamin SA, Capen CC, Hahn FF (eds). Pathobiology of the Aging Dog, 1st edn, Vol. 2. Iowa State University Press: Ames, 2000, pp 118–126.

    Google Scholar 

  21. Wong CL, Roberts MB, Wai MK . Effect of morphine and naloxone on intestinal transit in mice. Eur J Pharmacol 1980; 64: 289–295.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C Peters.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abbott, D., Comby, P., Charuel, C. et al. Preclinical safety profile of sildenafil. Int J Impot Res 16, 498–504 (2004). https://doi.org/10.1038/sj.ijir.3901232

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901232

Keywords

This article is cited by

Search

Quick links